Cytogen's ProstaScint wins FDA nod

Article

The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year. ProstaScint is licensed

The Food and Drug Administration has granted Cytogen of Princeton,NJ, a license to market its ProstaScint monoclonal antibody agentfor prostate cancer imaging. Cytogen plans to have ProstaScinton the market by early next year.

ProstaScint is licensed for two indications: to image newlydiagnosed patients whose biopsy-proven prostate cancer is at highrisk of metastasizing to pelvic lymph nodes, and for post-prostatectomypatients in whom there is a suspicion of cancer recurrence.

Cytogen has licensed ProstaScint rights for the urologicalmarket to C.R. Bard's urologic division, while Cytogen will retainrights to the medical imaging market (SCAN 8/28/96).

Cytogen is hoping that ProstaScint will prove to be more successfulthan its OncoScint CR/OV product for imaging colorectal and ovariancancer. The company plans to support ProstaScint through its Partnersin Excellence program, which is designed to help ensure that nuclearmedicine physicians are reading monoclonal antibody scans correctly(SCAN 9/25/96).

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.